BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30075505)

  • 1. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
    Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
    Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
    Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
    Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
    McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
    Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
    Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
    Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
    Wang J; Chai YL; Wang T; Liu JH; Dai PG; Liu Z
    Exp Mol Pathol; 2015 Jun; 98(3):407-10. PubMed ID: 25773678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
    Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
    Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
    Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
    Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.
    Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W
    Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.
    Martell K; McIntyre JB; Abedin T; Kornaga EN; Chan AMY; Enwere E; Köbel M; Dean ML; Phan T; Ghatage P; Lees-Miller SP; Doll CM
    Int J Gynecol Pathol; 2024 Mar; 43(2):158-170. PubMed ID: 37668363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution.
    Kinjyo Y; Nagai Y; Toita T; Kudaka W; Ariga T; Shimoji Y; Nakasone T; Taira Y; Arakaki Y; Nakamoto T; Wakayama A; Ooyama T; Maemoto H; Heianna J; Aoki Y
    Br J Radiol; 2017 Aug; 90(1076):20170241. PubMed ID: 28707541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m
    Isohashi F; Takano T; Onuki M; Arimoto T; Kawamura N; Hara R; Kawano Y; Ota Y; Inokuchi H; Shinjo H; Saito T; Fujiwara S; Sawasaki T; Ando K; Horie K; Okamoto H; Murakami N; Hasumi Y; Kasamatsu T; Toita T
    Int J Clin Oncol; 2019 May; 24(5):575-582. PubMed ID: 30580379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
    Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
    Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.
    Tharavichitkul E; Lorvidhaya V; Kamnerdsupaphon P; Sukthomya V; Chakrabandhu S; Klunklin P; Onchan W; Supawongwattana B; Pukanhaphan N; Galalae R; Chitapanarux I
    BMC Cancer; 2016 Jul; 16():501. PubMed ID: 27435245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T; Lingying W; Manni H; Jusheng A; Ning L
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R; Zhang H; Zou L; Qu Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.